The AI-native private longevity team,
built for Asian biology.
Healthcare treats you when you're sick. Nobody manages you while you're healthy. We built the system that does — proven in Taiwan, now coming to the Asian communities of the Western world.
Modern healthcare is built to treat disease.
Your health is what gets ignored.
Annual check-ups hand you a report of red flags — then nothing happens for 364 days. Your labs live in one portal, your wearable in another, your doctor sees you eleven minutes a year. The resources exist; the system doesn't.
For the Asian diaspora in the Western world — starting with the Taiwanese- and Chinese-American communities of California — it's worse: no clinician who understands their biology, their language, or their family's health culture. Insurance covers their sickness. Nobody owns their health.
We give every member a private longevity team — physicians, data, and an AI health manager — that owns the question no one else will: "how do we keep you well?"
2028: 1,000 members in California.
By Q3 2028, ĒSEN serves 1,000 paying members across the top Taiwanese- and Chinese-American communities of California — each with a 360° genetic baseline, an AI health manager in their pocket, and a clinical team behind it.
Eleven years of earning trust.
The Taiwan engine is proven.
1,326 active patients in the last twelve months (711 new), 6,900+ patient records, 205 members already genetically tested (237 panels), and a flagship that generated NT$20.06M before its grand opening even happened. Corporate channels are opening: Aspire International — the concierge team behind the AMEX Centurion Card — begins selling ĒSEN memberships around year-end.
Figures reconciled to bank receipts and live EHR (Aug 2026). Full financial detail available in the data room.
The US beachhead, validated by year-end 2027.
| Milestone | Target · EOY 2027 |
|---|---|
| NOX Virtual members — our flagship US product: a full private longevity team, delivered virtually (founding cohort NT$200K/yr, capped) | 100 |
| 360 Genetic Test + Emerson subscribers — US$1,000 test, then the AI health manager at US$40/mo (US$20/mo annual) | 400 |
| Taiwan NOX full-annual members | 150–250 |
| Taiwan operations | Sustained profitability |
Emerson, by mid-2027
Every member sees their reports, their data, and exactly where their care plan stands — in one place, in their language, powered by the clinical protocols we validated on real members in Taiwan. Emerson is the health manager; Harrison, its operational twin, is why one care staff serves 50+ members.
The sequence
Now → 2027 H1 invite-only: ĒSEN Club community events, waitlist-capped first 100–500 2027 Q3–Q4 ĒSEN Club public launch in California Late 2027 → 2028 local lab partners for in-market testing & tracking
Deliberate investment, disciplined engine.
| H1 2026 actual | Direction | |
|---|---|---|
| Revenue | NT$32.1M | FY2026 tracking ~2× FY2025 |
| Gross margin (mature clinic) | ~60% | Rising with membership mix |
| Operating cash flow | −NT$2.2M/mo | By design, during flagship scale-up; bridged by bank facilities, not cost cuts |
| Membership cash model | Annual, paid up-front — members fund working capital | |
The 2028 operating target this raise unlocks: ~US$10M ARR, majority-recurring revenue across subscriptions, memberships, and B2B channels — with clinics as the data and trust engine competitors can't copy.
Detailed statements, debt schedule and cap table available in the data room under NDA.
One team that owns your health, for life.
A one-stop private longevity team — managing your metabolic health, sleep, hormones and inflammation before they become disease — with clinics, labs, and an AI that knows a decade of your biology. Licensed to partners, compounding across every market the Asian diaspora calls home.
A doctor and an engineer.
Brothers, building for a decade.
Healthcare startups die one of two deaths: medical founders who can't build systems, or tech founders who can't earn clinical trust. We closed both failure modes by birth.
Dr. Wilson Tsou — Founder & CEO — designs the protocols, sees the patients, earns the trust. Every product decision is grounded in the exam room.
Shawn Tsou — Co-founder — engineer-background operator: turns craft medicine into replicable systems — SOPs, data, finance, AI implementation.
Six years of hands-on building — a clinic and pharmacy from the ground up, serving modern professionals through metabolic, sleep, and hormonal health — gave us the full longevity-care playbook, from manual to systemic. Wilson's protocols become Shawn's systems; Shawn's metrics feed Wilson's clinical iteration. That loop is the company. 93.1% of our visits come from patients who came back.
What we're honest about needing
Join us as partners, not just capital.
Raising a US$2–3M Pre-A.
First closes are open now. 18–24 months of runway to prove the membership engine: 40% product & engineering · 30% go-to-market · 15% clinical product & data · 15% operating scale. The milestone is proof — recurring membership, measurable outcomes, and the first repeatable cross-border channel.
We're looking for investors who bring the networks above — medical partners, community, credibility — to build the health management system for the Asian population of the Western world, who today cannot find doctors who understand their biology.
Talk to Shawn & Wilson